Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
295
-
Total 13F shares, excl. options
-
51.3M
-
Shares change
-
-2.94M
-
Total reported value, excl. options
-
$2.5B
-
Value change
-
-$235M
-
Put/Call ratio
-
0.61
-
Number of buys
-
149
-
Number of sells
-
-170
-
Price
-
$48.74
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q3 2025
366 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q3 2025.
HAEMONETICS CORP - Common Stock (HAE) has 295 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.3M shares
.
Largest 10 shareholders include BlackRock, Inc. (6.02M shares), VANGUARD GROUP INC (4.83M shares), NEUBERGER BERMAN GROUP LLC (3.67M shares), AQR CAPITAL MANAGEMENT LLC (2.13M shares), STATE STREET CORP (1.8M shares), River Road Asset Management, LLC (1.65M shares), UBS Group AG (1.45M shares), ROYAL BANK OF CANADA (1.26M shares), FMR LLC (1.22M shares), and GEODE CAPITAL MANAGEMENT, LLC (1.2M shares).
This table shows the top 295 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.